SCHEMBL27094487

SCHEMBL27094487

O=C(O)NC[C@H]1C[C@@H](c2ccccc2)Oc2cccnc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.40
▸ HTT P42858 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ ADORA3 P0DMS8 1/20 0.36
▸ AR P10275 1/20 0.36
▸ CYP19A1 P11511 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ LTA4H P09960 5/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ RAB9A P51151 1/20 0.35
▸ TSHR P16473 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ SLC8A1 P32418 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27094572 1.00 KDM4E (0.40) KDM4EHTTALDH1A1LMNAMEN1
SCHEMBL30030920 0.85 ACACB (0.42) KDM4EHTTALDH1A1LMNAMAOB
SCHEMBL30031141 0.85 ACACB (0.42) KDM4EHTTALDH1A1LMNAMAOB
SCHEMBL27094582 0.82 GAA (0.38) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL27094593 0.82 GAA (0.38) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL27094485 0.82 GAA (0.38) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL27094488 0.81 HTT (0.41) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL27094530 0.81 HTT (0.41) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL27094555 0.72 GAA (0.37) HTTLMNAMEN1KMT2ATSHR
SCHEMBL27094834 0.72 GAA (0.37) HTTLMNAMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-07-11 — — US disclosed
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-05-09 — — US disclosed
EP-4324834-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-02-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 KDM4E 2764/4885HTT 4062/4885ALDH1A1 1669/4885
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 KDM4E 2764/4885HTT 4062/4885ALDH1A1 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback